New drug cocktail aims to wipe out leukemia more deeply
NCT ID NCT07228273
First seen Nov 15, 2025 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This study tests whether adding venetoclax to a standard chemotherapy regimen (FLAG IDA) can achieve deeper remission in adults aged 18–65 with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. About 102 participants will be randomly assigned to the new combination or standard treatment. The goal is to see if the new approach leads to a higher rate of complete remission with no detectable cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.